Medtronic PLC $MDT Stock Purchased by GRIMES & Co WEALTH MANAGEMENT LLC

Posted by Geri Gentry on Nov 3rd, 2026

GRIMES & Co WEALTH MANAGEMENT LLC grew its stake in shares of Medtronic PLC (NYSE:MDT – Free Report) by 20.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 216,289 shares of the medical technology company’s stock after acquiring an additional 36,709 shares during the period. GRIMES & Co WEALTH MANAGEMENT LLC’s holdings in Medtronic were worth $18,664,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. BOCHK Asset Management Ltd bought a new stake in shares of Medtronic during the third quarter worth approximately $3,452,000. Signature Equity Partners LLC increased its stake in shares of Medtronic by 63.1% during the third quarter. Signature Equity Partners LLC now owns 561 shares of the medical technology company’s stock worth $48,000 after purchasing an additional 217 shares during the period. Summit Wealth Group LLC Co. increased its stake in shares of Medtronic by 26.8% during the third quarter. Summit Wealth Group LLC Co. now owns 3,482 shares of the medical technology company’s stock worth $300,000 after purchasing an additional 737 shares during the period. Landaas & Co. WI ADV bought a new position in shares of Medtronic during the third quarter worth approximately $209,000. Finally, MBA Advisors LLC increased its stake in shares of Medtronic by 10.8% during the third quarter. MBA Advisors LLC now owns 4,383 shares of the medical technology company’s stock worth $378,000 after purchasing an additional 427 shares during the period. Institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling

In other Medtronic news, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the transaction, the executive vice president directly owned 105,916 shares in the company, valued at $10,167,936. The trade was a 8.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Geoffrey Martha sold 50,000 shares of Medtronic stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the transaction, the chief executive officer owned 277,866 shares in the company, valued at approximately $26,397,270. The trade was a 15.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 61,903 shares of company stock worth $5,889,203. Company insiders own 0.27% of the company’s stock.

Medtronic Trading Up 2.9%

Shares of NYSE:MDT opened at $99.34 on Tuesday. The company has a market capitalization of $127.08 billion, a P/E ratio of 24.47, a P/E/G ratio of 2.22 and a beta of 0.55. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The business’s 50 day simple moving average is $91.82 and its 200 day simple moving average is $88.36.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The company’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend was Friday, September 25th. Medtronic’s dividend payout ratio is 70.94%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Robert W. Baird boosted their price target on Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research note on Wednesday, September 2nd. BTIG Research lowered their price objective on Medtronic from $100.00 to $99.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Royal Bank Of Canada reissued an “outperform” rating and set a $118.00 target price on shares of Medtronic in a report on Wednesday, September 2nd. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $92.00 target price on shares of Medtronic in a report on Thursday, September 3rd. Finally, Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Wednesday, October 14th. Eighteen research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $102.88.

View Our Latest Analysis on Medtronic

Medtronic Profile

(Free Report)

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.